Blessing Agunwamba

4.6k total citations
5 papers, 263 citations indexed

About

Blessing Agunwamba is a scholar working on Molecular Biology, Oncology and Psychiatry and Mental health. According to data from OpenAlex, Blessing Agunwamba has authored 5 papers receiving a total of 263 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 3 papers in Oncology and 1 paper in Psychiatry and Mental health. Recurrent topics in Blessing Agunwamba's work include Cancer Immunotherapy and Biomarkers (3 papers), Melanoma and MAPK Pathways (3 papers) and CAR-T cell therapy research (2 papers). Blessing Agunwamba is often cited by papers focused on Cancer Immunotherapy and Biomarkers (3 papers), Melanoma and MAPK Pathways (3 papers) and CAR-T cell therapy research (2 papers). Blessing Agunwamba collaborates with scholars based in United States and Germany. Blessing Agunwamba's co-authors include William F. Feely, Margaret K. Callahan, Jedd D. Wolchok, Matthew M. Burke, Alexander M. Lesokhin, Harriet M. Kluger, Mario Sznol, Naiyer A. Rizvi, Stephanie Anne Kronenberg and Michael A. Postow and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and PLoS Genetics.

In The Last Decade

Blessing Agunwamba

5 papers receiving 260 citations

Peers

Countries citing papers authored by Blessing Agunwamba

Since Specialization

Citations

This map shows the geographic impact of Blessing Agunwamba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Blessing Agunwamba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Blessing Agunwamba more than expected).

Fields of papers citing papers by Blessing Agunwamba

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Blessing Agunwamba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Blessing Agunwamba. The network helps show where Blessing Agunwamba may publish in the future.

Co-authorship network of co-authors of Blessing Agunwamba

This figure shows the co-authorship network connecting the top 25 collaborators of Blessing Agunwamba. A scholar is included among the top collaborators of Blessing Agunwamba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Blessing Agunwamba. Blessing Agunwamba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

#	Work	Indexed citations
1	Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). 2014 ·Journal of Clinical Oncology ·Mario Sznol, Harriet M. Kluger, Margaret K. Callahan, Michael A. Postow, (unknown), Neil H. Segal, Naiyer A. Rizvi, Alexander M. Lesokhin, Michael B. Atkins, John M. Kirkwood, Matthew M. Burke, Amanda Ralabate, (unknown), Stephanie Anne Kronenberg, Blessing Agunwamba, William F. Feely, Hong Qin, (unknown), Ashok K. Gupta, Jedd D. Wolchok	63
2	Survival, Response Duration, and Activity By Braf Mutation (Mt) Status in a Phase 1 Trial of Nivolumab (Anti-Pd-1, Bms-936558, Ono-4538) and Ipilimumab (Ipi) Concurrent Therapy in Advanced Melanoma (Mel) 2014 ·Annals of Oncology ·Harriet M. Kluger, Mario Sznol, Margaret K. Callahan, Michael A. Postow, Ruth Ann Gordon, Neil H. Segal, Naiyer A. Rizvi, Alexander M. Lesokhin, M.B. Atkins, John M. Kirkwood, Matthew M. Burke, Amanda Ralabate, (unknown), Stephanie Anne Kronenberg, Blessing Agunwamba, William F. Feely, Q. Hong, (unknown), Jedd D. Wolchok	17
3	Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). 2014 ·Journal of Clinical Oncology ·Mario Sznol, Harriet M. Kluger, Margaret K. Callahan, Michael A. Postow, Ruth Ann Gordon, Neil H. Segal, Naiyer A. Rizvi, Alexander M. Lesokhin, Michael B. Atkins, John M. Kirkwood, Matthew M. Burke, Amanda Ralabate, Angel L. Rivera, Stephanie Anne Kronenberg, Blessing Agunwamba, William F. Feely, Quan Hong, Suba Krishnan, Ashok Gupta, Jedd D. Wolchok	118
4	Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL). 2013 ·Journal of Clinical Oncology ·Jedd D. Wolchok, Harriet M. Kluger, Margaret K. Callahan, Michael A. Postow, Ruth Ann Gordon, Neil H. Segal, Naiyer A. Rizvi, Alexander M. Lesokhin, Kathleen Reed, Matthew M. Burke, Anne Caldwell, Stephanie Anne Kronenberg, Blessing Agunwamba, William F. Feely, Quan Hong, Christine E. Horak, Alan J. Korman, Jon M. Wigginton, Ashok Gupta, Mario Sznol	29
5	The CPEB Protein Orb2 Has Multiple Functions during Spermatogenesis in Drosophila melanogaster 2012 ·PLoS Genetics ·Shuwa Xu, Nathaniel Hafer, Blessing Agunwamba, Paul Schedl	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact